

4.5: Summary

The following table provides a summary of treatments for Type II diabetes. The different types of insulins used for Type I diabetes are summarized in Figure 4.8.

Table 4.1 Pharmacological properties of Type II diabetes treatments.

	TARGET	FUNCTIONAL GROUP	EFFECT	SUFFIX	WEIGHT CHANGE	Side Effects
Biguanides	Electron Transport Chain	Biguanide	1) Reduce glucogenesis 2) Increase insulin sensitivity 3) Reduces absorption	-formin	Neutral / Decrease	Lactic Acidosis
Sulfonylureas	K _{ATP} channel	Sulfonylurea	Directly stimulate insulin release	-ide	Increase	Weight gain / hypoglycemia / cardiac issues
Meglitinides	K _{ATP} channel	Benzamide*	Directly stimulate insulin release	-inide	Increase	Weight gain / hypoglycemia / cardiac issues
DPP-4 Inhibitors	DPP-4	Azolopyrimidines*	Increase GLP1 function (indirectly stimulate insulin)	-liptin	Neutral / Decrease	Pancreatitis
GLP1 Agonists	GLP1 receptor	GLP1 / Exadin-4 peptide template	Increase GLP1 function (indirectly stimulate insulin)	N/A	Neutral / Decrease	Nausea / GI issues
SGLT2 Inhibitors	SGLT-2	C-Linked glycosides	Prevent Glucose reabsorption	-flozin	Decrease	Urinary infections / dehydration
α-Glucosidases	α-glucosidase	N-linked glucose	Prevent glucose absorption	N/A	Decrease	Nausea / GI issues
Thiazolidinediones	PPAR _γ	Thiazolidinediones	Increase glucose utilization	-azone	Increase	Increase bone fractures

This page titled [4.5: Summary](#) is shared under a [not declared](#) license and was authored, remixed, and/or curated by [Elvin D. de Araujo](#), [Bilal Saqib](#), [Jeffrey W. Keillor](#), and [Patrick T. Gunning](#) (eCampus Ontario) via [source content](#) that was edited to the style and standards of the LibreTexts platform.